Moleculin Biotech (MBRX) Return on Capital Employed (2016 - 2026)
Moleculin Biotech (MBRX) posted quarterly Return on Capital Employed of 174.5% for Q4 2025, up 550.0% year-over-year from 26.85% in Q4 2024, and down 10.2% quarter-over-quarter from 158.34% in Q3 2025.
Moleculin Biotech (MBRX) Return on Capital Employed (2016 - 2026) Analysis & Trends
Moleculin Biotech's Return on Capital Employed history runs 10 years deep, the most recent figure standing at 174.5% for Q4 2025.
- In Q4 2025, Return on Capital Employed rose 550.0% year-over-year to 174.5%; the TTM figure through Dec 2025 stood at 174.5% (up 550.0% YoY), while the FY2025 annual figure was 198.11%, down 7817.0% from the prior year.
- Return on Capital Employed for Q4 2025 stood at 174.5%, down from 158.34% in the prior quarter.
- The five-year high for Return on Capital Employed was 22.77% in Q2 2021, with the low at 214.58% in Q1 2025.
- The 5-year median for Return on Capital Employed is 71.52% (2023), against an average of 93.39%.
- The sharpest annual moves came in 2021 and 2025: Return on Capital Employed jumped 5725 bps in 2021, then plunged 11859 bps in 2025.
- Moleculin Biotech's Return on Capital Employed stood at 27.75% in 2021, then sank by 95 bps to 54.16% in 2022, then tumbled by 71 bps to 92.44% in 2023, then plunged by 95 bps to 179.99% in 2024, then increased by 3 bps to 174.5% in 2025.
- Business Quant data shows MBRX's Return on Capital Employed at 174.5% in Q4 2025, 158.34% in Q3 2025, and 190.0% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.89 Bn | 131.04 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 86.05 Bn | 78.06 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 65.56 Bn | 60.38 Bn | 1.37 Bn | - |
| 4 | Moderna | 55.46 Bn | 50.32 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 42.12 Bn | 37.02 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.62 Bn | 28.31 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 27.70 Bn | 9.30 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.51 Bn | 26.35 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.38 Bn | 26.54 Bn | - | 7.88% |
| 10 | Moleculin Biotech | 3.32 Mn | 3.32 Mn | - | -217.35% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -217.35% |
| Dec 31, 2025 | -174.50% |
| Sep 30, 2025 | -158.34% |
| Jun 30, 2025 | -190.00% |
| Mar 31, 2025 | -214.58% |
| Dec 31, 2024 | -179.99% |
| Sep 30, 2024 | -153.06% |
| Jun 30, 2024 | -123.43% |
| Mar 31, 2024 | -95.99% |
| Dec 31, 2023 | -92.44% |
| Sep 30, 2023 | -70.40% |
| Jun 30, 2023 | -72.64% |
| Mar 31, 2023 | -64.86% |
| Dec 31, 2022 | -54.16% |
| Sep 30, 2022 | -45.74% |
| Jun 30, 2022 | -36.87% |
| Mar 31, 2022 | -31.27% |
| Dec 31, 2021 | -27.75% |
| Sep 30, 2021 | -24.30% |
| Jun 30, 2021 | -22.77% |